摘要
目的探讨米力农治疗风湿性心脏瓣膜病心功能不全的应用价值。方法将120例风湿性心脏瓣膜病患者随机分为对照组和治疗组,每组60例,其中对照组实施常规治疗,治疗组在对照组基础上加用米力农,评估两组患者的心功能,测定心脏指数。结果治疗组总有效率明显高于对照组,差异具有统计学意义(P<0.05);心排量、射血分数、心脏指数均优于对照组,各指标差异具有统计学意义(P<0.05)。结论米力农治疗风湿性心脏瓣膜病心功能不全效果显著,不良反应少。
Objective To explore the therapeutic effect of milrinone for rheumatic valvular heart disease with cardiac insufficiency. Methods 120 cases were divided randomly into two groups of 60 cases each, the therapeutic group were given add-on milrinone by intravenous drip based on conventional therapy while control group were only given conventional therapy. Results The total effective rate of the therapeutic group was higher than control group（P〈0.05）. The cardiac output, cardiac index and ejection fraction in the therapeutic group had obviously increased, there was a significant difference compared with control group（P〈0.05）. Conclusion Milrinone are effective and safe drugs for rheumatic valvular heart disease with cardiac insufficiency.
出处
《中国继续医学教育》
2015年第15期139-140,共2页
China Continuing Medical Education
关键词
米力农
风湿性心脏瓣膜病
心功能不全
Milrinone
Rheumatic valvular heart disease
Cardiac insufficiency
